文献速递白血病淋巴瘤

慢性淋巴细胞白血病患者的免疫球蛋白使用、生存与感染结局

Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2025-01-01

该回顾性纵向研究纳入澳大利亚维多利亚州2008至2022年6217例慢性淋巴细胞白血病(CLL)患者,描述免疫球蛋白替代治疗(IgRT)模式并探索其与严重感染的关联。随访14年间,发生严重感染的患者月度比例翻倍,接受任何IgRT的患者比例增至四倍。在定期接受预防性IgRT的患者中,IgRT期间感染发生率高于无IgRT期间,严重感染与IgRT的启动、重启及停止均相关。

要点

  • 14年随访期间,CLL患者严重感染的月度比例翻倍,接受任何IgRT的比例增至四倍。
  • 发生严重感染者死亡率0.090(95%CI 0.074-0.110),无严重感染者0.008(95%CI 0.007-0.009)。
  • 定期IgRT患者中,IgRT期间感染发生率0.056(95%CI 0.052-0.060),高于无IgRT期间的0.038(95%CI 0.035-0.042)。

核心结论

  • 在CLL患者中,严重感染与IgRT的启动、重启及停止均相关,IgRT与感染之间的因果关系需进一步研究评估。

研究设计与样本

  • 回顾性纵向研究,使用澳大利亚维多利亚州2008至2022年关联医院数据,纳入6217例CLL患者。
  • 采用Kaplan-Meier生存分析估计生存率、感染发生率和IgRT使用情况,采用Cox生存分析探索定期预防性IgRT患者中感染与IgRT的关联。

主要发现

  • 14年随访期间,发生严重感染的患者月度比例翻倍,接受任何IgRT的患者比例增至四倍。
  • 从CLL诊断至死亡的中位时间为10年;发生严重感染者死亡率0.090(95%CI 0.074-0.110),高于无严重感染者的0.008(95%CI 0.007-0.009)。
  • 共753例(12.1%)接受IgRT,其中524例(8.4%)定期接受IgRT。
  • 在定期接受IgRT的患者中,IgRT期间感染发生率为0.056(95%CI 0.052-0.060),高于无IgRT期间的0.038(95%CI 0.035-0.042)。
  • 严重感染与IgRT的启动、重启及停止均相关。

局限性

  • 原文指出需进一步研究评估IgRT与感染之间的因果关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with chronic lymphocytic leukemia (CLL) often experience infections due to immune suppression and/or dysregulation. Hypogammaglobulinemia is a key contributor to immunosuppression in CLL, and immunoglobulin replacement therapy (IgRT) is commonly given to prevent infections. However, the benefit of IgRT in preventing serious infections in CLL remains unclear. This study aimed to describe IgRT treatment patterns in a large, real-world cohort of patients with CLL, and explore the association between IgRT and serious infections. We conducted a retrospective longitudinal study of linked hospital data, including 6217 patients with CLL between 2008 and 2022 in Victoria, Australia. Kaplan-Meier survival analyses were performed to estimate survival, infection incidence, and IgRT use. Cox survival analyses explored associations between infections and IgRT in patients receiving regular prophylactic IgRT. Over the 14-year follow-up, the monthly proportion of patients experiencing serious infections doubled, while the proportion of patients receiving any IgRT quadrupled. The median time to death from CLL diagnosis was 10 years, and patients with serious infections had a higher mortality rate (0.090 [95% confidence interval (CI), 0.074-0.110]) vs those without (0.008 [95% CI, 0.007-0.009]). In total, 753 patients (12.1%) received IgRT, and 524 (8.4%) received IgRT regularly. In patients who received regular IgRT, infection incidence was higher during periods of IgRT (0.056 [95% CI, 0.052-0.060]) compared with periods without IgRT (0.038 [95% CI, 0.035-0.042]). Serious infections were associated with not only IgRT initiation and reinitiation, but also cessation. Further research is needed to evaluate the causal relationship between IgRT and infections in this population.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Carrillo de Albornoz S, Zhang X, Arnolda R, et al. Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia. Blood Adv. 2025. PMID: 40742276. doi:10.1182/bloodadvances.2025015867

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。